Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

62.67USD
21 Jul 2017
Change (% chg)

$-0.37 (-0.59%)
Prev Close
$63.04
Open
$62.89
Day's High
$63.09
Day's Low
$62.60
Volume
759,608
Avg. Vol
791,478
52-wk High
$63.09
52-wk Low
$43.14

BAX.N

Chart for BAX.N

About

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled... (more)

Overall

Beta: 0.68
Market Cap(Mil.): $34,071.74
Shares Outstanding(Mil.): 543.67
Dividend: 0.16
Yield (%): 1.02

Financials

  BAX.N Industry Sector
P/E (TTM): 18.68 32.10 15.85
EPS (TTM): 3.36 -- --
ROI: 13.84 13.54 -8.31
ROE: 20.92 15.90 -7.95

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Jul 20 2017

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Jul 20 2017

BRIEF-Baxter appoints Cathy R. Smith to its board

* Appointed Cathy R. Smith, executive vice president and cfo of target corp, to its board ​

Jul 17 2017

BRIEF-Baxter announces agreement with Dorizoe Lifesciences to further expand generic injectables pipeline

* Baxter announces agreement with dorizoe lifesciences to further expand generic injectables pipeline

Jun 14 2017

BRIEF-Baxter announces U.S. FDA approval, commercial launch of ready-to-use clindamycin injection in saline

* Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline

Jun 07 2017

BRIEF-Third Point Llc reports a stake of 7.5 pct in Baxter International

* Third Point Llc reports a stake of 7.5 percent in Baxter International as of June 1

Jun 02 2017

BRIEF-Baxter and Mayo Clinic launch R&D collaboration to transform patient care

* Baxter and Mayo Clinic launch research and development collaboration to transform patient care

May 31 2017

BRIEF-Third Point LLC dissolves share stake in Apple, Goldman Sachs

* Third Point LLC dissolves share stake in Apple Inc - sec filing

May 12 2017

BRIEF-Baxter International says in April became aware of criminal investigation by antitrust division of DOJ- SEC filing

* in April 2017, co became aware of criminal investigation by U.S. DOJ, antitrust division and federal jury in U.S. District court for eastern district of Pennsylvania-filing

May 04 2017

BRIEF-Baxter International says received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology

* Baxter International Inc - received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology

May 03 2017

Earnings vs. Estimates